NCT07022483
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07022483
Title Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements Yes
Sponsors Daiichi Sankyo
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Mount Sinai Medical Center RECRUITING Miami Beach Florida 33140 United States Details
Trials365 LLC RECRUITING Shreveport Louisiana 71103 United States Details
Avera Medical Group Gynecologic Oncology Sioux Falls RECRUITING Sioux Falls South Dakota 57105 United States Details
Zhejiang Cancer Hospital RECRUITING Hangzhou China Details
Jiangxi Maternal and Child Health Hospital RECRUITING Nanchang China Details
Yantai Yuhuangding Hospital RECRUITING Yantai China Details
Hyogo Cancer Center RECRUITING Akashi-shi Japan Details
NHO Kyushu Cancer Center RECRUITING Fukuoka Japan Details
Fukushima Medical University Hospital RECRUITING Fukushima Japan Details
Cancer Institute Hospital of JFCR RECRUITING Kōtoku Japan Details
Niigata Cancer Center Hospital RECRUITING Niigata Japan Details
Gunma Prefectural Cancer Center NOT_YET_RECRUITING Ota-shi Japan Details
NHO Hokkaido Cancer Center RECRUITING Sapporo Japan Details
Yamagata University Hospital RECRUITING Yamagata Japan Details
Samsung Medical Center RECRUITING Seoul South Korea Details
National Taiwan University Hospital RECRUITING Taipei Taiwan Details
Taipei Veterans General Hospital RECRUITING Taipei Taiwan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field